MICHAEL SEVERINO - 06 May 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)

Signature
Steven L. Scrogham, attorney-in-fact for Michael Severino
Issuer symbol
ABBV
Transactions as of
06 May 2022
Net transactions value
-$45,336,288
Form type
4
Filing time
10 May 2022, 17:05:03 UTC
Previous filing
05 Apr 2022
Next filing
16 May 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Options Exercise $4,045,382 +74,309 +49% $54.44 226,412 06 May 2022 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $1,409,408 +25,691 +11% $54.86 252,103 06 May 2022 Direct
transaction ABBV Common Stock, $0.01 par value Sale $6,030,418 -40,176 -16% $150.10 211,927 06 May 2022 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale $6,950,166 -45,988 -22% $151.13 165,939 06 May 2022 Direct F2
transaction ABBV Common Stock, $0.01 par value Sale $2,100,028 -13,836 -8.3% $151.78 152,103 06 May 2022 Direct F3
transaction ABBV Common Stock, $0.01 par value Options Exercise $3,637,163 +66,299 +44% $54.86 218,402 09 May 2022 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $1,984,315 +33,701 +15% $58.88 252,103 09 May 2022 Direct
transaction ABBV Common Stock, $0.01 par value Sale $7,060,059 -47,215 -19% $149.53 204,888 09 May 2022 Direct F4
transaction ABBV Common Stock, $0.01 par value Sale $4,777,080 -31,714 -15% $150.63 173,174 09 May 2022 Direct F5
transaction ABBV Common Stock, $0.01 par value Sale $3,190,571 -21,071 -12% $151.42 152,103 09 May 2022 Direct F6
transaction ABBV Common Stock, $0.01 par value Options Exercise $4,167,468 +70,779 +47% $58.88 222,882 10 May 2022 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $1,793,001 +29,221 +13% $61.36 252,103 10 May 2022 Direct
transaction ABBV Common Stock, $0.01 par value Sale $3,457,483 -22,873 -9.1% $151.16 229,230 10 May 2022 Direct F7
transaction ABBV Common Stock, $0.01 par value Sale $4,344,321 -28,536 -12% $152.24 200,694 10 May 2022 Direct F8
transaction ABBV Common Stock, $0.01 par value Sale $7,426,163 -48,591 -24% $152.83 152,103 10 May 2022 Direct F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to Buy) Options Exercise $4,045,382 -74,309 -100% $54.44 0 06 May 2022 Common Stock 74,309 $54.44 Direct F10
transaction ABBV Option (Right to Buy) Options Exercise $1,409,408 -25,691 -28% $54.86 66,299 06 May 2022 Common Stock 25,691 $54.86 Direct F10
transaction ABBV Option (Right to Buy) Options Exercise $3,637,163 -66,299 -100% $54.86 0 09 May 2022 Common Stock 66,299 $54.86 Direct F10
transaction ABBV Option (Right to Buy) Options Exercise $1,984,315 -33,701 -32% $58.88 70,779 09 May 2022 Common Stock 33,701 $58.88 Direct F10
transaction ABBV Option (Right to Buy) Options Exercise $4,167,468 -70,779 -100% $58.88 0 10 May 2022 Common Stock 70,779 $58.88 Direct F10
transaction ABBV Option (Right to Buy) Options Exercise $1,793,001 -29,221 -29% $61.36 70,879 10 May 2022 Common Stock 29,221 $61.36 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.58 to $150.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.58 to $151.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.58 to $151.95 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.04 to $150.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.04 to $151.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.04 to $151.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.55 to $151.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.55 to $152.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.55 to $153.50 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).